Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy - PubMed (original) (raw)

Clinical Trial

Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy

Susan A Phillips et al. Diabetes. 2003 Mar.

Abstract

The relationship between insulin action and control of the adipocyte-derived factor adiponectin was studied in age- and weight-matched obese individuals with type 2 diabetes failing sulfonylurea therapy. After initial metabolic characterization, subjects were randomized to troglitazone or metformin treatment groups; all subjects received glyburide (10 mg BID) as well. Treatment was continued for 3 months. The extent of glycemic control after treatment was similar in both groups. However, the increase in maximal insulin-stimulated glucose disposal rate was greater following troglitazone therapy (+44%) compared with metformin treatment (+20%). Troglitazone treatment increased serum adiponectin levels nearly threefold. There was no change in serum adiponectin with metformin treatment. A positive correlation was found between increases in whole-body glucose disposal rates and serum adiponectin levels after troglitazone; no such relationship was seen with metformin. The adiponectin protein content of subcutaneous abdominal adipocytes was increased following troglitazone treatment and unchanged after metformin. Adiponectin release from adipocytes was also augmented with troglitazone treatment. Adiponectin was present in adipocytes and plasma in several multimeric forms; a trimer was the major form secreted from adipocytes. These results indicate that increases in adiponectin content and secretion are associated with improved insulin action but are not directly related to glycemic control. Modulation of adipocyte function, including upregulation of adiponectin synthesis and secretion, may be an important mechanism by which thiazolidinediones influence insulin action.

PubMed Disclaimer

Cited by

The Clinical Utility of Salivary Biomarkers in the Identification of Type 2 Diabetes Risk and Metabolic Syndrome.
Desai P, Donovan L, Janowitz E, Kim JY. Desai P, et al. Diabetes Metab Syndr Obes. 2020 Oct 9;13:3587-3599. doi: 10.2147/DMSO.S265879. eCollection 2020. Diabetes Metab Syndr Obes. 2020. PMID: 33116710 Free PMC article. Review.
Relevance and consequence of chronic inflammation for obesity development.
Ruck L, Wiegand S, Kühnen P. Ruck L, et al. Mol Cell Pediatr. 2023 Nov 14;10(1):16. doi: 10.1186/s40348-023-00170-6. Mol Cell Pediatr. 2023. PMID: 37957462 Free PMC article. Review.
Metformin increases plasma ghrelin in Type 2 diabetes.
Doogue MP, Begg EJ, Moore MP, Lunt H, Pemberton CJ, Zhang M. Doogue MP, et al. Br J Clin Pharmacol. 2009 Dec;68(6):875-82. doi: 10.1111/j.1365-2125.2009.03372.x. Br J Clin Pharmacol. 2009. PMID: 20002081 Free PMC article.
Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population.
Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Srikanthan K, et al. Int J Med Sci. 2016 Jan 1;13(1):25-38. doi: 10.7150/ijms.13800. eCollection 2016. Int J Med Sci. 2016. PMID: 26816492 Free PMC article. Review.
No effect of metformin on the innate airway hyperresponsiveness and increased responses to ozone observed in obese mice.
Shore SA, Williams ES, Zhu M. Shore SA, et al. J Appl Physiol (1985). 2008 Oct;105(4):1127-33. doi: 10.1152/japplphysiol.00117.2008. Epub 2008 Aug 14. J Appl Physiol (1985). 2008. PMID: 18703763 Free PMC article.

Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy - PubMed (original) (raw)